Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C

by Dr. Trupti Shirole on  December 4, 2011 at 5:03 PM Clinical Trials News
RSS Email Print This Page Comment
Font : A-A+

Bristol-Myers Squibb Co. will collaborate with a unit of Johnson & Johnson to study a potential combination therapy for chronic hepatitis C.
 Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C
Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C

The companies will test the potentially positive effects of combining Johnson & Johnson's drug TMC435 with Bristol-Myers Squibb's daclatasvir. The clinical trials will begin in the first half of 2012 and will include a combination of the two drugs, the drugs plus pegylated interferon and ribavirin, and the drugs plus ribavirin.

The terms of their partnership were not disclosed.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Hepatitis A Hepatitis B Vasculitis Reiki and Pranic Healing Silent Killer Diseases Liver Aplastic Anemia Hepatitis C Combination Therapy for High Blood Pressure Hepatitis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive